4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

29th - 30th October, 2020 | ILEC Conference Center and IBIS London Earls Court, 47 Lillie Road, London, SW6 1UD
CONFERENCE SPEAKERS
Advisors
Stefan Gluck
Stefan Gluck
Vice President,
Celgene, USA



Eugene Zhukovsky
Eugene Zhukovsky
Chief Scientific Officer,
Biomunex Pharmaceuticals, France



Sophia Karagiannis
Sophia Karagiannis
Professor, Translational Cancer Immunology and Immunotherapy,
King’s College London, UK



Speakers
Roy Baynes
Roy Baynes
Senior Vice President and Head, Global Clinical Development, Chief Medical Officer,
Merck Research Laboratories


 Roy Baynes is Senior Vice President and Head, Global Clinical Development and Chief Medical Officer at Merck Sharp & Dohme (MSD). He was previously Senior Vice President of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences and prior to that was Vice President Global Clinical Development and Therapeutic Area (TA) Head for Hematology / Oncology, at Amgen Inc. He graduated as a Medical Doctor and obtained a Master of Medicine and Doctor of Philosophy from the University of the Witwatersrand, Johannesburg, South Africa. He has had a long and distinguished career in the haematology-oncology-and stem cell transplantation fields, including drug development, basic research, clinical practice, clinical research, teaching and administration. He is a member of many international societies, including the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO), and has authored some 150 publications. He has been recurrently named among America’s top physicians. Before joining Amgen in 2002, he was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, an NCI designated Comprehensive Cancer Center, at Wayne State University, Detroit, Michigan, USA.


Shailendra Singh (Shelly)
Shailendra Singh (Shelly)
Chief Operating Officer,
MarketsandMarkets


Shailendra Singh (Shelly) is Chief Operating Officer of MnM and a member of its board. He focuses on global sales and client services functions, as well as commercial optimization at MarketsandMarkets. He has years of expe¬rience in global delivery and outsourcing sector in the IT/ Consulting/Analytics/Big Data sectors. Prior to MnM, he was leading the global sales, client services and commercial ef¬fectiveness functions for Mu Sigma, a unicorn company and a leading global provider of Decision Sciences and Big Data analytics solutions.


Steven F. Schellings
Steven F. Schellings
Associate Director, Cellular Therapy, Account Management,
Novartis, USA



Stefan Gluck
Stefan Gluck
Vice President,
Celgene, USA



Bruno Tullia
Bruno Tullia
Assistant Professor,
UPMC Hillman Cancer Center, USA



Lindy Durrant
Lindy Durrant
Professor, Cancer Immunotherapy,
University of Nottingham, UK



Junjian Liu
Junjian Liu
Vice President, Biologics Discovery,
Innovent Biologics, China



Sebastien Tabruyn
Sebastien Tabruyn
CSO,
TransCure bioServices SAS, France



Eugene Zhukovsky
Eugene Zhukovsky
Chief Scientific Officer,
Biomunex Pharmaceuticals, France



Andrew Sewell
Andrew Sewell
Professor, Division of Infection and Immunity,
Cardiff University, UK


Sewell group research is focused around T-cell ligands and the receptors that recognise them during infection, autoimmune disease, transplant rejection and cancer immunotherapy. The alpha-beta TCR can exploit the MHC class I presentation pathway to target any cell based on its expression of any protein in vivo, thereby accessing a far greater range of targets than are accessible to monoclonal antibodies. Our newer studies indicate that alpha-beta and gamma-delta TCRs can target neoplasms by other, novel mechanisms. We aim to exploit these findings to generate new, broad-spectrum cancer therapeutics.


Ann White
Ann White
Senior Principal Scientist,
UCB Celltech, UK



Sophia Karagiannis
Sophia Karagiannis
Professor, Translational Cancer Immunology and Immunotherapy,
King’s College London, UK



Scott Durum
Scott Durum
Head, Cytokines and Immunity,
NIH


Scott K. Durum PhD trained at Oak Ridge, National Jewish Denver and Yale before coming to the National Cancer Institute, National Institutes of Health where he is chief of the Section of Cytokines and Immunity. His lab has studied the role of cytokines in the immune system, with a long interest in the IL-7 pathway which is essential for T lymphocyte development and survival. His lab together with collaborators found gain-of-function mutations in the IL-7 receptor that drive acute lymphoblastic leukemia, the most common cancer in children. They are currently studying the mechanism of leukemogenesis and developing therapeutics to target the pathway. He also plays in NIH’s band, the Affordable Rock n Roll Act.


Ali Roghanian
Ali Roghanian
Assistant Professor, Cancer Immunology,
University of Southampton, UK



Jenny Schroeder
Jenny Schroeder
Group Leader, Global R&D Discovery Solutions,
Lonza, Germany



Soldano Ferrone
Soldano Ferrone
Professor of Surgery,
Harvard University, USA



Sheeba Irshad
Sheeba Irshad
CRUK Clinician Scientist & Honorary Medical Oncologist,
Guy’s Hospital, UK



David Gilham
David Gilham
Vice President, R&D,
Celyad, UK



John Maher
John Maher
Chief Scientific Officer,
Leucid Bio, UK



Angela Vasaturo
Angela Vasaturo
Senior Field Application Scientist ,
Ultivue, UK



Aude De Gassart
Aude De Gassart
Director of Preclinical Research ,
ImCheck Therapeutics, France



Asher Nathan
Asher Nathan
CEO ,
NeoTX Therapeutics, Israel



Will Arends
Will Arends
Chartered (UK) and European Patent Attorney,
Marks & Clerk, UK



Vivian Barak
Vivian Barak
Head, Immunology Lab for Tumor Diagnosis,
Hadassah Medical Center, Israel



Stephen Harper
Stephen Harper
Group Leader, Protein Science,
Immunocore, UK



Markus Zettl
Markus Zettl
Director, Immuno-Oncology ,
Pieris Pharmaceuticals, Germany



Ian Pike
Ian Pike
Chief Scientific Officer,
Proteome Sciences


Ian Pike is the Chief Scientific Officer at Proteome Sciences and has 30 years’ experience working in the diagnostics and biotechnology sectors. Having gained a PhD in Medical Microbiology, he joined Welcome Diagnostics as a research group leader and spent 8 years working on new diagnostic assays, particularly for hepatitis. In December 1999, he joined the Technology Transfer Office of the UK Medical Research Council with responsibility for patents and commercialization of a wide portfolio of technologies related to the biomedical sector. Ian also worked for Cancer Research Ventures managing intellectual property and performing business development activities in Europe and the USA. Since joining Proteome Sciences in 2002 he has held a number of roles covering intellectual property management, business development, operational management and is now focused on leading the Company’s scientific strategy to offer clients a flexible, high quality service.


Pirouz Daftarian
Pirouz Daftarian
Senior Manager, Applications for Immunooncology and Vaccines ,
JSR Micro Life Sciences and MBL International



Fabienne Hermitte
Fabienne Hermitte
Vice President, Medical Affairs,
HalioDx



Saskia Roesch
Saskia Roesch
Global Product Manager, T-Cell Immunology,
Miltenyi Biotech



Renier Heijkants
Renier Heijkants
Senior Scientist,
APO-T



Nathalie Conte
Nathalie Conte
PDX Finder Project Lead,
The European Bioinformatics Institute



Marsilio Adriani
Marsilio Adriani
Principal Scientist,
4D Pharma



Christie Zhang
Christie Zhang
Project Team Leader,
Elstar Therapeutics



Graham Pawelec
Graham Pawelec
Professor,
University of Tuebingen



Justyna Rzepecka
Justyna Rzepecka
Principal Scientist Immunology,
Concept Lifesciences



Colin Self
Colin Self
CEO,
Precision Therapeutics



David Sansom
David Sansom
Professor,
University College London



Manish	Kumar
Manish Kumar
Product Manager Cells and Media,
PromoCell



Danny Wells
Danny Wells
Principal Investigator,
Parker Institute for Cancer Immunotherapy, USA



Debiprasad Roy
Debiprasad Roy
Senior Director, R&D Technology Platforms,
Allogene Therapeutics, USA